{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T09:28:48Z","timestamp":1745486928571,"version":"3.37.3"},"reference-count":37,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,9]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Therapy with an IL-15 superagonist resulted in immune and clinical responses in a transplant recipient with PML.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000664","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T15:31:09Z","timestamp":1591111869000},"page":"2387-2391","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post\u2013allogeneic hematopoietic stem cell transplant patient"],"prefix":"10.1182","volume":"4","author":[{"given":"Aabha","family":"Oza","sequence":"first","affiliation":[{"name":"Division of Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Rettig","sequence":"first","affiliation":[{"name":"Division of Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"Powell","sequence":"first","affiliation":[{"name":"Division of Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"O\u2019Brien","sequence":"first","affiliation":[{"name":"Division of Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5719-1555","authenticated-orcid":false,"given":"David B.","family":"Clifford","sequence":"first","affiliation":[{"name":"Department of Neurology, Washington University in St. Louis, St. Louis, MO;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Ritchey","sequence":"first","affiliation":[{"name":"Division of Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Gehrs","sequence":"first","affiliation":[{"name":"Division of Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Hollaway","sequence":"first","affiliation":[{"name":"Division of Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Major","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-2887","authenticated-orcid":false,"given":"Todd A.","family":"Fehniger","sequence":"first","affiliation":[{"name":"Division of Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Miller","sequence":"first","affiliation":[{"name":"McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Soon-Shiong","sequence":"first","affiliation":[{"name":"ImmunityBio, Inc., Culver City, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Rock","sequence":"first","affiliation":[{"name":"ImmunityBio, Inc., Culver City, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0429-3133","authenticated-orcid":false,"given":"John F.","family":"DiPersio","sequence":"first","affiliation":[{"name":"Division of Oncology and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"issue":"6","key":"2020060211305573500_B1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00401-015-1471-7","article-title":"Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS)","volume":"130","author":"Bauer","year":"2015","journal-title":"Acta Neuropathol"},{"issue":"10","key":"2020060211305573500_B2","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-12-2357","article-title":"Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor \u03b1Su\/Fc fusion complex in syngeneic murine models of multiple myeloma","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res"},{"issue":"2","key":"2020060211305573500_B3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/cyto.a.23303","article-title":"OMIP-042: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood","volume":"93","author":"Staser","year":"2018","journal-title":"Cytometry A"},{"issue":"10","key":"2020060211305573500_B4","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1073\/pnas.0709717105","article-title":"Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7","volume":"105","author":"Bakker","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"2020060211305573500_B5","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020060211305573500_B6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020060211305573500_B7","doi-asserted-by":"crossref","first-page":"e01748","DOI":"10.1128\/JVI.01748-17","article-title":"ALT-803 transiently reduces simian immunodeficiency virus replication in the absence of antiretroviral treatment","volume":"92","author":"Ellis-Connell","year":"2018","journal-title":"J Virol"},{"author":"Davis","key":"2020060211305573500_B8"},{"issue":"23","key":"2020060211305573500_B9","doi-asserted-by":"crossref","first-page":"e95128","DOI":"10.1172\/jci.insight.95128","article-title":"Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control","volume":"2","author":"Mah","year":"2017","journal-title":"JCI Insight"},{"issue":"7","key":"2020060211305573500_B10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00277-002-0481-4","article-title":"Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin\u2019s lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy","volume":"81","author":"Buckanovich","year":"2002","journal-title":"Ann Hematol"},{"issue":"9","key":"2020060211305573500_B11","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1212\/01.wnl.0000183064.10227.b5","article-title":"Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2","volume":"65","author":"Kunschner","year":"2005","journal-title":"Neurology"},{"issue":"11","key":"2020060211305573500_B12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.bmt.1701010","article-title":"Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2","volume":"20","author":"Przepiorka","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020060211305573500_B13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bmt.1701568","article-title":"Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy","volume":"23","author":"Re","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2020060211305573500_B14","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaneurol.2014.825","article-title":"Treatment of progressive multifocal leukoencephalopathy with interleukin 7","volume":"71","author":"Alstadhaug","year":"2014","journal-title":"JAMA Neurol"},{"issue":"2","key":"2020060211305573500_B15","doi-asserted-by":"crossref","first-page":"ofu074","DOI":"10.1093\/ofid\/ofu074","article-title":"Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy","volume":"1","author":"Gasnault","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"2020060211305573500_B16","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1097\/QAD.0000000000002278","article-title":"IL-7 immunotherapy for progressive multifocal leukoencephalopathy in a patient with already controlled HIV-1 infection on antiretroviral therapy","volume":"33","author":"Guille","year":"2019","journal-title":"AIDS"},{"issue":"5","key":"2020060211305573500_B17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s13365-018-0657-x","article-title":"Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia","volume":"24","author":"Harel","year":"2018","journal-title":"J Neurovirol"},{"issue":"2","key":"2020060211305573500_B18","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1212\/NXI.0000000000000213","article-title":"Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia","volume":"3","author":"Miskin","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"2020060211305573500_B19","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/jac\/dkq359","article-title":"A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia","volume":"65","author":"Patel","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2020060211305573500_B20","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciu682","article-title":"Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1","volume":"59","author":"Sospedra","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"306","key":"2020060211305573500_B21","doi-asserted-by":"crossref","first-page":"306ra151","DOI":"10.1126\/scitranslmed.aab1720","article-title":"JC polyomavirus mutants escape antibody-mediated neutralization","volume":"7","author":"Ray","year":"2015","journal-title":"Sci Transl Med"},{"issue":"10","key":"2020060211305573500_B22","doi-asserted-by":"crossref","first-page":"ofz374","DOI":"10.1093\/ofid\/ofz374","article-title":"Sustained response and rationale of programmed cell death-1-Targeting for progressive multifocal leukoencephalopathy","volume":"6","author":"Audemard-Verger","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"17","key":"2020060211305573500_B23","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2020060211305573500_B24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13365-019-00738-x","article-title":"Progressive multifocal leukoencephalopathy treated with nivolumab","volume":"25","author":"Hoang","year":"2019","journal-title":"J Neurovirol"},{"issue":"17","key":"2020060211305573500_B25","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMc1817193","article-title":"Treatment of progressive multifocal leukoencephalopathy with pembrolizumab","volume":"380","author":"Rauer","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"2020060211305573500_B26","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1056\/NEJMc1816198","article-title":"Treatment of progressive multifocal leukoencephalopathy with nivolumab","volume":"380","author":"Walter","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"2020060211305573500_B27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/bmt.2010.221","article-title":"Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient","volume":"46","author":"Balduzzi","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"2020060211305573500_B28","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2020060211305573500_B29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"2020060211305573500_B30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s13365-014-0289-8","article-title":"Progressive multifocal leukoencephalopathy therapy","volume":"21","author":"Clifford","year":"2015","journal-title":"J Neurovirol"},{"issue":"11","key":"2020060211305573500_B31","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1212\/WNL.0b013e3182a43e6d","article-title":"In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection","volume":"81","author":"Martin-Blondel","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"2020060211305573500_B32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/13550280600716604","article-title":"Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells","volume":"12","author":"W\u00fcthrich","year":"2006","journal-title":"J Neurovirol"},{"issue":"22","key":"2020060211305573500_B33","doi-asserted-by":"crossref","first-page":"11918","DOI":"10.1128\/JVI.77.22.11918-11926.2003","article-title":"Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy","volume":"77","author":"Du Pasquier","year":"2003","journal-title":"J Virol"},{"issue":"1","key":"2020060211305573500_B34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4049\/jimmunol.168.1.499","article-title":"Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope","volume":"168","author":"Koralnik","year":"2002","journal-title":"J Immunol"},{"issue":"2","key":"2020060211305573500_B35","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.18632\/oncotarget.12387","article-title":"Definition and characterization of novel HLA-*A02-restricted CD8+ T cell epitopes derived from JCV polyomavirus with clinical relevance","volume":"8","author":"Mani","year":"2017","journal-title":"Oncotarget"},{"issue":"Pt 9","key":"2020060211305573500_B36","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/brain\/awr206","article-title":"Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome","volume":"134","author":"Aly","year":"2011","journal-title":"Brain"},{"issue":"3","key":"2020060211305573500_B37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.24574","article-title":"Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant","volume":"79","author":"Jelcic","year":"2016","journal-title":"Ann Neurol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/11\/2387\/1743383\/advancesadv2019000664.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/11\/2387\/1743383\/advancesadv2019000664.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T03:09:37Z","timestamp":1666753777000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/11\/2387\/460597\/Interleukin15-superagonist-N803-treatment-of-PML"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000664","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2020,6,2]]}}}